---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-134913"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2025-06-04T23:59:59+00:00"
generated_at: "2026-05-19T23:54:57.701551+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Trevi Therapeutics prices $100M common stock offering at $5.75 per share

## Summary
- Offering of 17.4M shares at $5.75/share; net proceeds ~$93.7M (~$107.8M if underwriters' option fully exercised).
- Underwriters granted 30-day option to purchase up to 2.61M additional shares at the same price.
- Proceeds to fund clinical development of Haduvio for chronic cough in IPF, non-IPF ILD, and RCC.
- Cash runway extended into 2029 based on current plans; additional capital needed for regulatory approval.
- Offering expected to close on June 5, 2025; Morgan Stanley, Leerink, Stifel, Cantor as joint book-runners.

## SEC filing metadata
- accession: 0001193125-25-134913
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2025-06-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000119312525134913/0001193125-25-134913-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000119312525134913/d34558d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-134913
- JSON: https://secwatch.observer/filing/0001193125-25-134913.json
- Plain text: https://secwatch.observer/filing/0001193125-25-134913.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.